Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 22, 2022

Primary Completion Date

May 17, 2022

Study Completion Date

June 2, 2022

Conditions

Viral InfectionCOVID-19

Interventions

DRUG

Molnupiravir

A single dose of R or T drug in each of 2 periods of the study in fasted conditions

Trial Locations (1)

"Limited Liability Company Research Center Eco-Safety", Saint Petersburg

All Listed Sponsors

lead

Valenta Pharm JSC

INDUSTRY